Sjögren's disease & overlap diseases
Increased risk of adverse gestational outcomes in pregnant women with primary Sjögren’s syndrome
Authors' conclusion
Compared with non-autoimmune controls, pregnancy in women with pSS presents more challenges. Importantly, we observed that the use of LMWH as anticoagulant therapy is an independent protective measure for fetal survival.
Study context
- Population
- Pregnant individuals with primary Sjögren's syndrome (pSS) receiving outpatient or inpatient care across multiple hospitals in Anhui Province, China, January 2015 to December 2022
- Participants
- 164 vs 328
- Exposure
- Pregnant women with pSS vs control subjects
- pSSn = 164
- Controln = 328reference
- Outcome
- Spontaneous miscarriage
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Therapeutic miscarriage
P < 0.05
Placental abnormalities on prenatal US
P < 0.05
Congenital heart abnormalities in live-born neonates
P < 0.05
Fetal survival vs fetal loss within pSS pregnancies
- Greater use of prophylactic anticoagulant therapy in the fetal survival group
- Low molecular weight heparin (LMWH) an independent protective factor for fetal survival
Original publication
Increased risk of adverse gestational outcomes in pregnant women with primary Sjögren’s syndrome. RMD Open. Published 28 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →